Arcellx develops cell therapies utilizing its proprietary D-Domain technology and ddCAR platform to enhance the efficacy of immune cell treatments for cancer. The company targets relapsed or refractory multiple myeloma, aiming to provide patients with durable responses through its innovative CART-ddBCMA therapy.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KPFounders
Product
Problem
Patients with relapsed or refractory multiple myeloma face limited treatment options, and existing therapies often fail to provide durable responses. Traditional cell therapies can suffer from challenges related to safety, efficacy, and accessibility, hindering their widespread application.
Solution
Arcellx is developing novel cell therapies designed to overcome the limitations of existing treatments for cancer and autoimmune diseases. The company's approach leverages its proprietary D-Domain technology and ddCAR and ARC-SparX platforms to enhance the efficacy and safety of immune cell therapies. Arcellx's lead asset, anitocabtagene autoleucel (anito-cel), is a ddCAR-T therapy targeting the BCMA antigen and is currently in Phase 2 clinical trials for relapsed or refractory multiple myeloma. The ARC-SparX platform enables the creation of dosable, controllable, and adaptable cell therapies by combining universal ARC-T cells with specialized SparX proteins that bind to and kill targeted disease cells. This approach aims to improve T-cell associated toxicity and enhance safety.
Target Audience
Arcellx's primary target audience includes patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, generalized myasthenia gravis and solid tumors, as well as healthcare providers specializing in hematological malignancies and autoimmune diseases.
Features
- D-Domain Technology: Utilizes a small, stable, fully synthetic binding protein with a hydrophobic core.
- ddCAR Platform: Engineered T cells expressing D-Domain based CARs that target a specific antigen on diseased cells.
- ARC-SparX Platform: Combines universal ARC-T cells and specialized SparX proteins for targeted cell killing.
- Anitocabtagene autoleucel (anito-cel): A ddCAR-T therapy targeting the BCMA antigen for multiple myeloma.
- Controllable T-cell activation: ARC-T cells are inactivated until they bind to a SparX protein bound to a diseased cell, making T cell killing functions controllable and dependent on the dose of SparX protein.
- Potential to address antigen loss: More than one type of SparX protein can potentially be given simultaneously, which may address antigen loss or heterogeneity of diseased cells and improve efficacy of therapy.